Moreover, adeno-associated virus-mediated overexpression of LACTB prominently enhanced the tumour-inhibiting effect of lenvatinib in a mouse model, suggesting that the combination of lenvatinib and LACTB may be helpful for the treatment of patients with liver cancer for whom lenvatinib alone has low efficacy. The gene discussed is LACTB; the disease is liver cancer.